A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition:   Metastatic Hepatocellular Carcinoma Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: ADI-PEG 20 Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Safety and Feasibility of Immuno-OCT
Conditions:   Colon Carcinoma;   Barrett Esophagus;   Gastrointestinal Dysplasia Intervention:   Drug: Bevacizumab-800CW Sponsor:   University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition:   Colorectal Cancer Metastatic Interventions:   Drug: Tunlametinib plus Vemurafenib;   Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition:   Metastatic Hepatocellular Carcinoma Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: ADI-PEG 20 Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition:   Colorectal Cancer Metastatic Interventions:   Drug: Tunlametinib plus Vemurafenib;   Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Safety and Feasibility of Immuno-OCT
Conditions:   Colon Carcinoma;   Barrett Esophagus;   Gastrointestinal Dysplasia Intervention:   Drug: Bevacizumab-800CW Sponsor:   University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition:   Metastatic Hepatocellular Carcinoma Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: ADI-PEG 20 Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition:   Colorectal Cancer Metastatic Interventions:   Drug: Tunlametinib plus Vemurafenib;   Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Safety and Feasibility of Immuno-OCT
Conditions:   Colon Carcinoma;   Barrett Esophagus;   Gastrointestinal Dysplasia Intervention:   Drug: Bevacizumab-800CW Sponsor:   University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition:   Colorectal Cancer Metastatic Interventions:   Drug: Tunlametinib plus Vemurafenib;   Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Condition:   Metastatic Hepatocellular Carcinoma Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: ADI-PEG 20 Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Condition:   Colorectal Cancer Metastatic Interventions:   Drug: Tunlametinib plus Vemurafenib;   Drug: Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab Sponsor:   Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Safety and Feasibility of Immuno-OCT
Conditions:   Colon Carcinoma;   Barrett Esophagus;   Gastrointestinal Dysplasia Intervention:   Drug: Bevacizumab-800CW Sponsor:   University Medical Center Groningen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials

Single Arm Phase II Trial Using Canakinumab for the Prevention of Lung Cancer (Can-Prevent-Lung)
Condition:   Lung Cancer Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: ADI-PEG 20 Sponsor:   M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials